CSL Behring Australia

What CSL Behring Australia does

CSL Behring Australia (CSL Behring (Australia) Pty Ltd) is a wholly-owned subsidiary of CSL Limited (ASX:CSL), the world's fifth-largest biotechnology company, and operates Australia's only commercial-scale plasma manufacturing operation. Established in 1994 at 189 Camp Road, Broadmeadows, Victoria, the company manufactures plasma-derived and recombinant biotherapies for rare and serious diseases including haemophilia A and B, primary immunodeficiencies, chronic inflammatory demyelinating polyneuropathy (CIDP), hereditary angioedema, and cardiovascular conditions. Its product portfolio includes the recombinant single-chain factor VIII AFSTYLA and albumin fusion factor IX IDELVION for haemophilia; HIZENTRA, PRIVIGEN and INTRAGAM 10 immunoglobulin therapies; albumin for critical care; CSL112 (apolipoprotein A-I) in Phase 3 AEGIS-II trials for post-myocardial infarction cardiovascular events; and a historic COVID-19 immunoglobulin. Manufacturing is centred on the Broadmeadows plasma fractionation facility — described as the largest of its kind in the Southern Hemisphere — which processes over 10 million litres of plasma annually after a 9x capacity uplift enabled by the AUD$900 million facility expansion completed in December 2022.

Name

CSL Behring Australia

Legal name

CSL Behring (Australia) Pty Ltd

Website

https://cslbehring.com.au

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

CSL Behring Australia manufactures plasma-derived and recombinant biotherapies for rare and serious diseases at the world's largest plasma fractionation facility in Broadmeadows. The CSL Limited subsidiary supplies Australian patients under a nine-year National Fractionation Agreement with the National Blood Authority.

Ownership category

akta.pro rank

Product category

Plasma-Derived Biotherapies

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421), Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Plasma Fractionation & Purification Manufacturing (HLAIAHAI)

akta.pro secondary industries

Plasma Collection & Donor Services (Plasmapheresis Centers) (HLAIAHAH), Plasma-Derived Coagulation Factors (Hemophilia Therapies) (HLAIAHAB), Plasma-Derived Therapy Cold Chain & Specialty Logistics (HLAIAHAL), Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG)

Keywords

• Plasma-derived biotherapies
• Recombinant protein therapies
• Plasma fractionation manufacturing
• Rare disease treatments
• Biopharmaceutical contract manufacturing

Headquarters

HQ city

Broadmeadows

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Infrastructure, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Plasma-derived Biotherapies: CSL Behring's core revenue stream from plasma-derived therapeutic proteins including coagulation factors, immunoglobulins, and albumin products sold to healthcare providers and governments worldwide.
2. National Fractionation Agreement: Nine-year agreement (2018-2026) with Australian National Blood Authority to supply plasma-derived therapies manufactured domestically, representing a significant government contract revenue stream.
3. Vaccines (via Seqirus): CSL's Seqirus subsidiary produces influenza vaccines including seasonal flu vaccines and pandemic preparedness solutions.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

CSL Behring Australia develops, manufactures, and supplies plasma-derived and recombinant biotherapies for the treatment of rare and serious diseases including haemophilia, immune deficiencies, CIDP, cardiovascular and neurological conditions. The company operates the largest plasma fractionation facility in the Southern Hemisphere at Broadmeadows, Victoria, processing over 10 million litres of plasma annually to produce coagulation factors, immunoglobulins, albumin and other therapies supplied to the Australian National Blood Authority and healthcare providers globally.

Product overview

CSL Behring Australia is a global biotherapeutics company offering a portfolio of innovative biotherapies for rare and serious diseases. The product portfolio includes plasma-derived and recombinant products organized across therapeutic areas including: haemophilia treatments (AFSTYLA for Haemophilia A, IDELVION for Haemophilia B), immunoglobulin therapies (HIZENTRA, PRIVIGEN, INTRAGAM 10 for immunodeficiencies and CIDP), cardiovascular therapies (CSL112 in development for heart attack recovery), albumin products for critical care, and COVID-19 Immunoglobulin. The company operates state-of-the-art manufacturing facilities in Broadmeadows, Victoria, including plasma fractionation and advanced recombinant manufacturing capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• AFSTYLA (Antihemophilic Factor (Recombinant), Single Chain) Recombinant Factor VIII single-chain therapy for the treatment and control of bleeding episodes in patients with haemophilia A, approved in over 40 countries including Australia, Japan, EU, US and Switzerland.
• IDELVION (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) Long-acting recombinant Factor IX albumin fusion protein for the treatment of haemophilia B, approved in over 40 countries including Australia, Japan, EU, US and Switzerland.
• HIZENTRA (Normal Immunoglobulin (Human) 20%, Subcutaneous Injection) Subcutaneous immunoglobulin therapy approved by the TGA as the first subcutaneous immunoglobulin for maintenance therapy in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and for primary immunodeficiencies; enables self-administration at home.
• PRIVIGEN Intravenously administered immunoglobulin therapy for primary immunodeficiencies and CIDP.
• INTRAGAM 10 Intravenous immunoglobulin therapy for CIDP and other immune disorders.
• CSL112 (Apolipoprotein A-I (Human)) Novel apolipoprotein A-I infusion therapy in Phase 3 (AEGIS-II) clinical trial for reducing early recurrent cardiovascular events following acute myocardial infarction.
• COVID-19 Immunoglobulin (CoVIg-19) Hyperimmune globulin product developed using plasma donations from recovered COVID-19 patients, with potential to treat serious COVID-19 complications; developed by the CoVIg-19 Plasma Alliance including CSL Behring.
• Albumin (Albumin Products manufactured at Broadmeadows) Plasma-derived albumin products used in critical care for burns, shock, transplant support and other conditions; produced at the Broadmeadows advanced manufacturing facility with 100+ tonnes annual capacity per module.
• National Fractionation Service (Australian Plasma Fractionation) Contract-manufacturing and supply service under the National Fractionation Agreement with the Australian National Blood Authority — domestic plasma fractionation producing a comprehensive portfolio of plasma-derived therapies for Australian patients.

Quantifiable outcome

• 9x capacity increase in Australian plasma processing capability
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• LaTrobe University (In2science Program)minorStrategic or Co-development Partner · 7 October 2020Four-year partnership with LaTrobe University-led In2science program to deliver STEM education programs in local Broadmeadows schools, reaching more than 150 year 7-10 students annually in the Hume Local Council Area. CSL Behring employees serve as classroom mentors.
• University of Queensland (UQ)coreStrategic or Co-development Partner · 5 June 2020CSL partnered with UQ and CEPI to advance development and manufacture of UQ's COVID-19 'molecular clamp' vaccine candidate. CSL appointed as Trusted Manufacturer for clinical development and large-scale manufacturing. Initial production planned at CSL's Melbourne facilities with capacity for up to 100 million doses.
• CEPI (Coalition for Epidemic Preparedness Innovations)coreStrategic or Co-development Partner · 1 January 2020CEPI and CSL partnered to fund development and manufacture of UQ's COVID-19 vaccine candidate. CEPI provided up to US$10.6 million for rapid response molecular clamp vaccine platform development. CSL and CEPI share costs for clinical development and manufacture.
• CoVIg-19 Plasma AlliancecoreStrategic or Co-development Partner · 1 January 2020Unprecedented collaboration of leading plasma companies including CSL Behring, Takeda, Biotest, BPL, LFB, Octapharma, and others to develop anti-coronavirus hyperimmune intravenous immunoglobulin medicine. The Alliance worked with NIH on Phase 3 clinical trials (ITAC study). Bill & Melinda Gates Foundation provided advisory support.
• Australian Red Cross Blood Service (Lifeblood)coreStrategic or Co-development Partner · 1 January 2020Partnership for collection of plasma donations from recovered COVID-19 patients for development of COVID-19 Immunoglobulin product. Lifeblood collects plasma donations with high antibody levels from eligible recovered COVID-19 patients for use in clinical trials.
• AstraZenecaminorStrategic or Co-development Partner · 1 January 2020CSL and AstraZeneca agreed for CSL to manufacture approximately 50 million doses of the Oxford University vaccine candidate AZD1222 for supply to Australia.
• National Blood Authority (Australia)coreStrategic or Co-development Partner · 11 December 2017Nine-year National Fractionation Agreement (commencing 1 January 2018, ending 31 December 2026) with Australian National Blood Authority representing all Australian governments. CSL Behring supplies comprehensive portfolio of plasma products manufactured at Broadmeadows for Australian patients.
• World Federation of Haemophilia (WFH)coreStrategic or Co-development Partner · 1 January 2009CSL Behring was the first biotechnology leader to provide coagulation factor donations and financial support for the WFH Humanitarian GAP Program in a multi-year agreement in 2009. The partnership aims to improve diagnosis and treatment of bleeding disorders in developing countries. In 2018, CSL shipped more than 10 million IUs of haemophilia medicines to WFH.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Roche: Major global pharmaceutical and diagnostics company with overlap in immunology and rare disease therapeutic areas where CSL Behring competes, though not a plasma fractionation specialist.
• Pfizer: Global pharmaceutical incumbent that inherited Wyeth's haematology franchise (where CSL CEO Paul Perreault previously worked). Overlaps with CSL Behring in selected rare disease and biopharmaceutical adjacencies, but does not focus on plasma fractionation.

Direct peers

• Sanquin: Dutch not-for-profit blood supply organization that also fractionates plasma into therapies. Comparable to CSL Behring's vertically integrated plasma collection-to-fractionation model, particularly relevant given CSL's Australian Red Cross Lifeblood partnership.
• Biotest: German specialty plasma and biotherapeutic company focused on immunology, haematology, and critical care. Direct competitor to CSL Behring in plasma-derived immunoglobulins and clotting factors and a CoVIg-19 Alliance participant.
• Takeda Pharmaceutical: Acquired Shire in 2019, making it a top global plasma-derived therapies player alongside CSL Behring. Competes directly in immunoglobulin, haemophilia, and rare disease franchises, and is a member of the same CoVIg-19 Plasma Alliance.
• Octapharma: Swiss private plasma products manufacturer with a global footprint across coagulation factors, immunoglobulins, and critical care. Competes with CSL Behring in essentially every plasma-derived therapeutic area and is a peer in the CoVIg-19 Alliance.
• Bio Products Laboratory (BPL): UK-based plasma product manufacturer with global reach in immunoglobulins and coagulation therapies. Competes with CSL Behring across plasma-derived portfolios and was a CoVIg-19 Alliance member.
• Grifols: Spanish-headquartered global leader in plasma-derived therapies with a vertically integrated plasma collection network. Directly competes with CSL Behring across immunoglobulins, coagulation factors, and albumin, and is a co-member of competitive consortia including CoVIg-19 Plasma Alliance efforts.
• Kedrion Biopharma: Italian plasma-derived therapeutics company operating nationally managed fractionation agreements similar to CSL Behring's Australian NBA contract. Direct competitor in plasma fractionation for rare and serious diseases globally.
• LFB: French plasma fractionator and biopharmaceutical manufacturer operating across coagulation, immunology, and critical care. Direct peer in the plasma-derived therapy space and fellow member of the CoVIg-19 Plasma Alliance.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/csl
• YouTubeyoutube.com/user/CSLGroup
• Facebookfacebook.com/CSLBiopharma
• LinkedInlinkedin.com/company/csl-limited
• Instagraminstagram.com/cslbiotechnology

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CSL Behring Australia